皮肤恶性黑色素瘤是皮肤肿瘤中恶性程度较高的一类，其发病率虽低，但临床发现较晚、容易转移，因此死亡率较高。目前早发现、早诊断、早治疗仍是降低该病的死亡率的关键。皮肤恶性黑色素瘤好发于白色人种，但近年来我国的发病率逐年上升，严重危害着人们的生命健康。我国对于皮肤恶性黑色素瘤的诊断与治疗在不断发展，但仍存在许多争议，缺乏统一的标准。本文作者就近年来对该病诊断与治疗方法的研究进展作一综述。

[1] ANNA B A,WOJCIECH J,KRZYSZTOF R,et al.Melanin content in melanoma metastases affects the outcome of radiotherapy[J].Oncotarget,2016,7(14):17844-17853.
[2] MENGZE H,GANG Z,XIAOLING D,et al.Clinical characteristics and prognostic indicators for metastatic melanoma:data from 446 patients in north China[J].Tumour Biol,2016,37(8):10339-10348.
[3] ARNOLD M,DE V E,WHITEMAN D C,et al.Global burden of cutaneous melanoma attributable to ultraviolet radiation in 2012[J].Int J Cancer,2018,143(6):1305-1314.
[4] IVES N J,SUCIU S,EGGERMONT A M M,et al.Adjuvant interferon-α for the treatment of high-risk melanoma:an individual patient data meta-analysis[J].Eur J Cancer,2017,82:171-183.
[5] FEIGELSON H S,POWERS J D,KUMAR M,et al.Melanoma incidence,recurrence,and mortality in an integrated healthcare system:a retrospective cohort study[J].Cancer Med,2019,8(9):4508-4516.
[6] SHI K,ZHU X,LIU Z,et al.Clinical characteristics of malignant melanoma in central China and predictors of metastasis[J].Oncol Lett,2020,19(2):1452-1464.
[7] TEMAM S,MAMELLE G,MARANDAS P,et al.Postoperative radiotherapy for primary mucosal melanoma of the head and neck[J].Cancer,2005,103(2):313-319.
[8] CSCO黑色素瘤专家委员会.中国黑色素瘤诊治指南[M].北京:人民卫生出版社,2015.
[9] 陈万青,郑荣寿,曾红梅,等.2011年中国恶性肿瘤发病和死亡分析[J].中国肿瘤,2015,24(1):1-10.
[10] YU J,LUO X,HUANG H,et al.Clinical characteristics of malignant melanoma in Southwest China:a single-center series of 82 consecutive cases and a Meta-analysis of 958 reported cases[J].PLoS One,2016,11(11):e165591.
[11] SCHUURMAN M S,WAAL A C,THIJS E J M,et al.Risk factors for second primary melanoma among Dutch patients with melanoma[J].Br J Dermatol,2017,176(4):971-978.
[12] CSCO黑色素瘤专家委员会.中国黑色素瘤诊疗规范[M].北京:人民卫生出版社,2018.
[13] VESTERGAARD M E,MACASKILL P,HOLT P E,et al.Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma:a Meta-analysis of studies performed in a clinical setting[J].Br J Dermatol,2008,159(3):669-676.
[14] 中国医疗保健国际交流促进会,华夏皮肤影像人工智能协作组,中国医疗保健国际交流促进会皮肤科分会皮肤影像学组,等.中国皮肤恶性黑素瘤皮肤镜特征专家共识[J].中华皮肤科杂志,2020,53(6):401-408.
[15] MALVEHY J,HAUSCHILD A,CURIEL-LEWANDROWSKI C,et al.Clinical performance of the Nevisense system in cutaneous melanoma detection:an international,multicentre,prospective and blinded clinical trial on efficacy and safety[J].Br J Dermatol,2014,171(5):1099-1107.
[16] ARMIN G,MARCO W,UWE L,et al.Diagnostic image analysis of malignant melanoma in in vivo confocal laser-scanning microscopy:a preliminary study[J].Skin Res Technol,2008,14(3):359-363.
[17] BALCH C M,GERSHENWALD J E,SENG-JAW S,et al.Multivariate analysis of prognostic factors among 2,313 patients with stage Ⅲ melanoma:comparison of nodal micrometastases versus macrometastases[J].J Clin Oncol,2010,28(14):2452-2459.
[18] ROBINSON A V,KEEBLE C,LO M C I,et al.The neutrophil-lymphocyte ratio and locoregional melanoma:a multicentre cohort study[J].Cancer Immunol Immunother,2020,69(4):559-568.
[19] JEFFREY E G,RICHARD A S,KENNETH R H,et al.Melanoma staging:evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual[J].CA Cancer J Clin,2017,67(6):472-492.
[20] BOAVA S L,GABRIEL P,VILAVERDE S J.Imaging tests in cutaneous malignant melanoma staging:a retrospective cohort[J].An Bras Dermatol,2020,95(1):106-108.
[21] TRAN K T,WRIGHT N A,COCKERELL C J.Biopsy of the pigmented lesion-when and how[J].J Am Acad Dermatol,2008,59(5):852-871.
[22] GILL P,HOWELL J,NAUGLER C,et al.Utility of multistep protocols in the analysis of sentinel lymph nodes in cutaneous melanoma:an assessment of 194 cases[J].Arch Pathol Lab Med,2019,143(9):1126-1130.
[23] NIELSEN P S,RIBER-HANSEN R,SCHMIDT H,et al.Automated quantification of proliferation with automated hot-spot selection in phosphohistone H3/MART1 dual-stained stage Ⅰ/Ⅱ melanoma[J/OL].Diagn Pathol,2016,11(1).https://doi.org/10.1186/s13000-016-0484-4.
[24] HIRSH V,PIGNATA S,BERSANELLI M,et al.Immunotherapy Bridge 2016 and Melanoma Bridge 2016:meeting abstracts[J/OL].J Transl Med,2017,15(1).https://doi.org/10.1186/s12967-016-1095-2.
[25] SIAVASH R,SONIA C,BOLAND G M.The role of surgery for melanoma in an era of effective systemic therapy[J].Curr Oncol Rep,2017,19(3):1-5.
[26] PETER G,KRZYSZTOF T D,MARIANNE N,et al.2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm:a randomised,multicentre trial[J].Lancet,2011,378(9803):471-477.
[27] ALASTAIR D M R,LAUREN E H,MICHAEL J Q,et al.The association between excision margins and local recurrence in 11,290 thin (T1) primary cutaneous melanomas:a case-control study[J].Ann Surg Oncol,2016,23(4):1082-1089.
[28] CHARLES M B,SENG-JAW S,MERRICK I R,et al.Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm):intergroup melanoma surgical trial[J].Ann Surg Oncol,2000,7(2):87-97.
[29] WHEATLEY K,WILSON J S,GAUNT P.Reply to response to Wheatley et al."Surgical excision margins in primary cutaneous melanoma:a Meta-analysis and Bayesian probability evaluation" Cancer Treatment Reviews April 2016;45:76[J].Cancer Treat Rev,2016,55(1):225-229.
[30] CHI Z,LI S,SHENG X,et al.Clinical presentation,histology,and prognoses of malignant melanoma in ethnic Chinese:a study of 522 consecutive cases[J/OL].BMC Cancer,2011,11(1).https://doi.org/10.1186/1471-2407-11-85.
[31] JASON P L,DEEPAK N,PAMELA R S,et al.Delay of surgery for melanoma among medicare beneficiaries[J].JAMA Dermatol,2015,151(7):731-741.
[32] CONIC R R Z,GASTMAN B R.Response to:reply to:"Determination of the impact of melanoma surgical timing on survival using the National Cancer Database"[J].J Am Acad Dermatol,2018,79(4):e73-e74.
[33] MORTON D L,THOMPSON J F,COCHRAN A J,et al.Final trial report of sentinel-node biopsy versus nodal observation in melanoma[J].N Engl J Med,2014,370(7):599-609.
[34] MURTHA T D,GANG H,DALE H.Predictors for use of sentinel node biopsy and the association with improved survival in melanoma patients who have nodal staging[J].Ann Surg Oncol,2018,25(4):903-911.
[35] SLADDEN M,ZAGARELLA S,POPESCU C,et al.No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy:critical appraisal of the multicenter selective lymphadenectomy trial-I final report[J].Br J Dermatol,2015,172(3):566-571.
[36] 徐宇,朱蕙燕,陈勇,等.前哨淋巴结活检在中国皮肤和肢端恶性黑色素瘤患者诊治中的临床意义[J].中国癌症杂志,2018,28(11):819-826.
[37] BAE Y C,JEONG D K,KIM K H,et al.Adequacy of sentinel lymph node biopsy in malignant melanoma of the trunk and extremities:clinical observations regarding prognosis[J].Arch Plast Surg,2020,47(1):42-48.
[38] DONALD L M,JOHN F T,ALISTAIR J C,et al.Sentinel-node biopsy or nodal observation in melanoma[J].N Engl J Med,2006,355(13):1307-1317.
[39] SABOL M,REKEN V,SABOLOVA L,et al.Recurrence after sentinel lymph node biopsy in cutaneous melanoma:a single-center experience in Slovak patients[J].Neoplasma,2019,66(4):647-651.
[40] MARK B F,JOHN F T,ALISTAIR J C,et al.Completion dissection or observation for sentinel-node metastasis in melanoma[J/OL].N Engl J Med,2017,376(23).https://doi.org/10.1111/dth.12544.
[41] LEITER U,STADLER R,MAUCH C,et al.Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT):a multicentre,randomised,phase 3 trial[J].Lancet Oncol,2016,17(6):757-767.